

IV. Listing of Claims

The Examiner required a listing of all claims readable upon the elected Group and Species.

1. (Presently Elected) A method of modulating the trafficking or activation of a leukocyte in an animal, said method comprising contacting myeloid lineage cells in said animal with a therapeutic amount of:
 - a) an agonist of a mammalian OX2 protein; or
 - b) an antagonist of a mammalian OX2 protein.
2. (Not elected)
3. (Not elected)
4. (Presently elected) The method of Claim 1, wherein said animal exhibits signs or symptoms of an inflammatory, infective, leukoproliferative, neurodegenerative, or post-traumatic condition.
5. (Presently elected) The method of Claim 4, wherein said sign or symptom is in neural tissue; lymphoid tissue; myeloid tissue; pancreas; gastrointestinal tissue; thyroid tissue; muscle tissue; or skin or collagenous tissue.
6. (Presently elected) The method of Claim 1, wherein said modulating is inhibiting function of said leukocyte cell.
7. (Presently elected) The method of Claim 6, wherein said administering is said agonist.
8. (Presently elected) The method of Claim 7, wherein said agonist is said mammalian OX2.
9. (Presently elected) The method of Claim 7, wherein said animal is experiencing signs or symptoms of autoimmunity; an inflammatory condition; an infection; tissue specific autoimmunity; degenerative autoimmunity; rheumatoid arthritis; atherosclerosis; multiple sclerosis; vasculitides; delayed hypersensitivities; skin grafting; a transplant; spinal injury; stroke; neurodegeneration; or ischemia.

10. (Presently elected) The method of Claim 7, wherein said administering is in combination with:

- a) an anti-inflammatory cytokine agonist or antagonist;
- b) an analgesic;
- c) an anti-inflammatory agent; or
- d) a steroid.

11. (Not elected)

12. (Not elected)

13. (Not elected)

14. (Not elected)

15. (Not elected)

16. (Presently elected) A method of modulating the activation of a leukocyte in a tissue, said method comprising contacting myeloid lineage cells in said tissue with:

- a) an agonist of a mammalian OX2 protein; or
- b) an antagonist of a mammalian OX2 protein.

17. (Presently elected) The method of Claim 16, wherein said modulating is inhibiting said leukocyte cell, and said contacting is with said agonist.

18. (Presently elected) The method of Claim 17, wherein said administering is in combination with:

- a) an anti-inflammatory cytokine agonist or antagonist;
- b) an analgesic;
- c) an anti-inflammatory agent; or
- d) a steroid.

19. (Not elected)

20. (Not elected)